Early sevoflurane sedation in severe COVID-19-related lung injury patients. A pilot randomized controlled trial.

ABSTRACT:

Background

This study aimed to assess a potential organ protective effect of volatile sedation in a scenario of severe inflammation with an early cytokine storm (in particular IL-6 elevation) in patients suffering from COVID-19-related lung injury with invasive mechanical ventilation and sedation.

Methods

This is a small-scale pilot multicenter randomized controlled trial from four tertiary hospitals in Switzerland, conducted between April 2020 and May 2021. 60 patients requiring mechanical ventilation due to severe COVID-19-related lung injury were included and randomized to 48-hour sedation with sevoflurane vs. continuous intravenous sedation (= control) within 24 h after intubation. The primary composite outcome was determined as mortality or persistent organ dysfunction

SUBMITTER: Beck-Schimmer B 

PROVIDER: S-EPMC10973324 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature